Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Merck (MRK) closed the most recent trading day at $117.23, moving -1.19% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. At the same time, the Dow added 1.26% ...

Development methodologies combine old and new techniques, but getting any new material into high-volume manufacturing is a ...

"PictorLabs receives funds to advance virtual staining in research settings" was originally created and published by Medical ...

Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...

The gross proceeds to the Company from the exercise of the Existing Warrants together with the sale of the new warrants is expected to be approximately $6.2 million. The closing of the transaction is ...

PictorLabs, a pioneering software company transforming histopathology with AI-powered virtual staining, announced today the successful completion of its $30 million Series B funding round. The round ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Under a MOU signed between both the parties, Merck and Siemens have decided to expand their cooperation in Smartfacturing.

Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, ...